aTyr Pharma Inc
471A
Company Profile
Business description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Contact
10240 Sorrento Valley Road
Suite 300
San DiegoCA92121
USAT: +1 858 731-8389
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
58
Stocks News & Analysis
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,118.30 | 2.60 | 0.03% |
| CAC 40 | 8,447.27 | 63.26 | 0.75% |
| DAX 40 | 24,910.41 | 16.40 | 0.07% |
| Dow JONES (US) | 51,999.67 | 328.64 | 0.64% |
| FTSE 100 | 10,494.21 | 63.59 | 0.61% |
| HKSE | 24,493.95 | 348.72 | -1.40% |
| NASDAQ | 26,376.34 | 307.60 | -1.15% |
| Nikkei 225 | 69,628.91 | 224.41 | 0.32% |
| NZX 50 Index | 13,405.00 | 21.13 | -0.16% |
| S&P 500 | 7,511.35 | 42.94 | -0.57% |
| S&P/ASX 200 | 8,905.00 | 4.20 | 0.05% |
| SSE Composite Index | 4,090.68 | 1.21 | -0.03% |